Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The effect of the intrauterine contraceptive device (IUD) on the composition of endometrial secretion has been studied using the monoclonal antibody D9B1. The antibody binds to a polypeptide-associated oligosaccharide epitope that is secreted by endometrial epithelium in the secretory phase with a maximum around the time of implantation. In endometria affected by the IUD in situ, a significant reduction in epitope expression has been observed using immunohistochemistry. This defect can occur against a background of normal secretory differentiation and in the expectation of normal ovarian stimulus. The data provide new insight into the contraceptive mechanisms of action of the IUD.

Original publication




Journal article



Publication Date





81 - 89


Barrier Methods, Biology, Contraception, Contraceptive Methods, Contraceptive Methods--side effects, Endometrial Effects, Endometrium, Family Planning, Genitalia, Genitalia, Female, Iud--side effects, Physiology, Urogenital System, Uterus, Adult, Endometrium, Epitopes, Female, Histocytochemistry, Humans, Immunoenzyme Techniques, Intrauterine Devices, Menstrual Cycle, Middle Aged, Oligosaccharides